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miodarone, an effective iodine-rich an-
tiarrhythmic drug, frequently causes ei-
ther changes in thyroid function tests 
or clinical thyroid dysfunction. Both 
amiodarone-induced thyrotoxicosis (AIT) and 
amiodarone-induced hypothyroidism (AIH) 
have an overall incidence of approximately 14-
18%, and AIT being most common in iodine-
deficient areas, AIH in iodine-sufficient areas. 
Both dysfunctions may develop either in appar-
ently normal thyroid glands or in glands with 
preexisting abnormalities (either nodular goiter 
or thyroid autoimmune disease). The most im-
portant pathogenic mechanisms of AIT include 
excess iodine-induced thyroid hormone synthe-
sis (type I AIT) and amiodarone (or iodine)-
related destructive thyroiditis (type II AIT), but 
mixed forms involving both pathogenic mecha-
nisms are likely more frequent than previously 
believed. AIT is a therapeutic challenge, because 
rapid restoration of euthyroidism is warranted in 
patients with underlying cardiac disorders. 
Treatment of choice for type I AIT is represented 
by the concomitant administration of thiona-
mides and potassium perchlorate, whereas ster-
oids are the most useful tool for type II AIT. 
Mixed (or, better, undefined) forms of AIT 
should be treated with a combination of thiona-
mides, potassium perchlorate and glucocorti-
coids. Radioiodine therapy is usually not feasi-
ble owing to low thyroidal radioiodine uptake 
due to iodine load, while thyroidectomy can be 
performed in cases resistant to medical therapy 
or in those patients requiring a rapid control of 
thyrotoxicosis after a short course with iopanoic 
acid to restore normal serum T3 levels. Thyroid 
ablation is usually required in type I and unde-
fined AIT, also because this allows safe reinsti-
tution of amiodarone treatment, if needed; fol-
low-up without treatment is sufficient in most 
patients with type II AIT, who usually remain 
euthyroid or may develop hypothyroidism after 
reexposure to iodine load. 
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thyroid dysfunction, Amiodarone-induced thyro-
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Introduction 
Amiodarone is an iodine-rich drug very ef-
fective in the management of tachyarrhyth-
mias1 (Fig. 1) and, to a lesser extent, of se-
vere congestive heart failure.2 However, this 
drug also has multiple undue effects on sev-
eral tissues and organs (Table 1); among 
these, the thyroid is often involved. Effects of 
amiodarone on the thyroid, range from ab-
normalities of thyroid function tests not asso-
ciated with changes in thyroid function to 
overt thyrotoxicosis (amiodarone-induced 
thyrotoxicosis, AIT) or hypothyroidism 
(amiodarone-induced hypothyroidism, AIH).3-5 
While AIH represents neither a difficult 
therapeutic problem nor a contraindication to 
continuing amiodarone treatment, AIT is a 
major therapeutic challenge, owing to its 
multifaceted features and the iodine load that 
makes the thyroid gland resistant to conven-
tional antithyroid drug treatment. The aim of 
this review article is to focus on pathogenic, 
clinical and therapeutic aspects of AIT.  
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Table 1. Side effects and complications of amiodarone therapy 
 
 Overall incidence (%) 
Corneal microdepositis 100 
Gastrointestinal changes (anorexia, nausea) 80 
Skin photosensivity and gray/bluish skin discloration 55-75 
Neurological symptome (ataxia, tremors, peripheral neuropathy) 48 
Abnormalities of liver function tests* 25 
Thyroid dysfunction 14-18 
Lung dysfunction, interstitial pneumonitis 10-13 
Epididymitis 11 
Cardiac disorders (heart block, sinus bradycardia) 2-3 
Gynecomastia Exceptional 
* toxic hepatitis is rare 
 
 
 
 
 
Fig.1. Molecular structure of amiodarone and 
desethylamiodarone 
 
Pharmacology of amiodarone 
Amiodarone contains approximately 37% 
iodine by weight.5 With a common daily dos-
age of 200-600 mg and an approximate 10% 
daily deiodination of the molecule, a huge 
amount of iodide (7-21 mg) is made available 
to the body every day, far in excess of neces-
sary requirements (100-150 µg) for a normal 
thyroid hormone production; this results in a 
severe iodine load.6 Amiodarone is distrib-
uted in several tissues, including the thyroid7 
(Table 2A), from which it is slowly released, 
with a mean elimination half-life of more 
than one month for amiodarone and almost 
two months for its main metabolite, desethyl-
amiodarone (DEA)8,9 (Table 2B). Metabolism 
of amiodarone follows different pathways, 
the most important being dealkylation which 
leads to DEA formation.8 
 
Table 2a. Pharmacokinetics of amiodarone 
Tissue A (µg/g) DEA (µg/g) A/DEA 
Adipose 316 72 4.2 
Liver 391 2354 0.12 
Lung 198 952 0.21 
Kidney 57 262 0.22 
Heart 40 169 0.24 
Muscle 22 51 0.43 
Thyroid 14 64 0.22 
Brain 8 54 0.15 
 
Table 2b. Pharmacokinetics of amiodarone 
Bio – availability 45% 
Serum peak levels 5-6 hours 
Half-life 25-90 days 
Adipose 
Liver 
Tissue distribution 
Lung 
 Kidney 
 Heart 
 Muscle 
 Thyroid 
 Brain 
    Liver 70% Elimination 
Kidney 25% 
 Other 5% 
 
In peripheral tissues, particularly in the 
liver, amiodarone inhibits type I 5’-
deiodinase (5’-D) activity, the enzyme which 
removes an atom of iodine from the outer 
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ring of thyroxine (T4) to generate triiodothy-
ronine (T3), and from the outer ring of reverse 
T3 (rT3) to produce 3, 3'-diiodothyronine (T2).
10 
In addition, the drug inhibits thyroid hor-
mones entry into peripheral tissues, espe-
cially in the liver. Both mechanisms contrib-
ute to an increase in serum T4 concentration; 
a decrease in serum T3 levels, and an in-
crease in serum rT3 concentration in euthy-
roid subjects given long-term amiodarone 
therapy. Amiodarone also causes an inhibi-
tion of type II 5’-D, mostly operating in the 
pituitary. This possibly contributes to amio-
darone-associated changes in serum thyrotro-
pin (TSH) concentration; serum TSH tends to 
increase during the initial phases of amiodar-
one treatment, but then it usually normalizes 
in patients who remain euthyroid (Table 3).  
 
Table 3. Thyroid function test in euthyroid pa-
tients treated with amiodarone 
 
 Short term 
therapy 
Long term ther-
apy 
Thyroxine Increased Slightly 
Increased/High 
Triiodiothyronine Decreased Normal 
Slightly 
Decreased/Low 
Reverse T3 Increased Normal 
Thyrotropin Increased Increased 
T3 sulfate Increased Normal 
 
Further to inhibition of type I and type II 
5’-D activities, amiodarone may induce a hy-
pothyroid-like condition at the tissue level, 
particularly in the heart, partly related to both 
a reduction in the number of catecholamine 
receptors and a decrease in the effect of T3-
adrenoceptors.10 The molecular mechanisms 
underpinning this antagonistic effect of 
amiodarone on thyroid hormone effects are 
not completely understood, but they might be 
related to the fact that DEA (but not amio-
darone) acts as a non-competitive inhibitor of 
T3 binding to thyroid hormone receptors.
11 
We have observed that in NIH3T3 cells, 
DEA (but not amiodarone) behaves as a weak 
thyroid hormone, and antagonizes the effect 
of Tα and TRβ agonist using both TR3 only 
when present in large excess.12 The high tis-
sues levels reached by the drug during 
chronic amiodarone treatment might explain 
the prevailing antagonist effect and the “hy-
pothyroid-like” situation observed in tissues 
such as the heart and liver.9,10  
Another important action of amiodarone 
and its metabolites is a direct cytotoxic effect 
on the thyroid,13-15 which may explain the 
thyroidal destructive phenomena occurring in 
type II AIT (see below). Effects of amiodar-
one and its metabolites on thyroid economy 
are summarized in Table 4.  
Although iodine may induce thyroid auto-
immune phenomena in humans and ani-
mals,16 most studies suggest that it is unlikely 
that amiodarone therapy be associated with 
the appearance of thyroid autoantibodies in 
patients with negative tests before amiodar-
one institution.5 However, it has been re-
ported that amiodarone administration may 
cause an increase in some lymphocyte sub-
sets;17 this might exacerbate preexisting thy-
roid-specific autoimmune phenomena,18 a 
mechanism that might be relevant particu-
larly for AIH. 
 
 
Table 4. Mechanism of amiodarone action on the thyroid 
Mechanism of action Effects 
Inhibition of type I 5’-deiodinase Increased T4 
Decreased T3 
Increased rT3 
Inhibition of type II 5’- deiodinase Increased TSH 
Inhibition of TH entry into the cells 
Decreased peripheral T3 pro-
duction 
Thyroid citotoxicity Leakage of preformed TH 
Interaction with TH receptors 
Decreased transcription of 
TH-responsive gene 
Tissue hypothyroid like condi-
tion 
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Amiodarone Induced Thyroid Dysfunction 
Most amiodarone-treated patients remain 
euthyroid, but, as mentioned above, a rele-
vant proportion of them develop either thyro-
toxicosis or hypothyroidism.9 The overall in-
cidence of amiodarone-induced thyroid dys-
function varies widely in different series, 
mostly due to diagnostic criteria, selection of 
patients and environmental iodine intake, but 
on on average it stands between 14% and 
18%.5 AIT is relatively more frequent in io-
dine-deficient areas, whereas AIH is rela-
tively more frequent in iodine-sufficient ar-
eas.18 In a cross-sectional study carried out in 
Western Tuscany (Italy) (moderately low io-
dine intake: urinary iodine excretion 68±40 
µg/g of creatinine) and Massachusetts (USA) 
(normal iodine intake: 185±21 µg/g), the in-
cidence of AIT was about 10% in Italy and 
2% in USA, while that of AIH was 5% in It-
aly and 22% in USA.18 In a prospective study 
of 58 consecutive amiodarone-treated pa-
tients from a Dutch region with moderately 
sufficient iodine intake, AIT occurred in 12% 
of cases and AIH in 7%.19 In a prospective 
study carried out in a moderately iodine-
deficient Italian area, AIT occurred in 15% of 
patients and AIH in 71% of patients who had 
evidence of preexisting Hashimoto’s thyroid-
itis.20,21 AIH may represent a transient phe-
nomenon in patients who do not have an un-
derlying chronic autoimmune thyroiditis.5 
Fig.2. Onset of thyrotoxicosis during and after 
amiodarone therapy 
 
Amiodarone Induced Thyrotoxicosis 
AIT has a relative predominance among 
men (M:F ratio of 3:1)5 and may develop 
early in the treatment, after many years of 
therapy, or, owing to the long half-life of 
amiodarone and its metabolites, even 9-12 
months after drug withdrawal (Fig.2). The 
occurrence of AIT seems to be unrelated to 
the daily or cumulative dose of amiodarone.19 
 
Pathogenesis 
Pathogenesis of AIT is complex and not 
completely understood. The disease may de-
velop both in a normal thyroid gland (type II 
AIT) or in a gland with preexisting abnor-
malities (type I AIT) (Table 4). Thyroid auto-
immune phenomena seems to play little, if 
any, role in the development of AIT in pa-
tients without underlying thyroid disorders or 
with nodular goiters, while they are important 
in patients with “latent” Graves’ disease prior 
to amiodarone administration.22 
Type I AIT is a true form of hyperthyroid-
ism (excessive thyroid hormone synthesis) 
triggered by iodine load. Intrathyroidal iodine 
content is markedly increased in all AIT pa-
tients, but there is no relevant impairment of 
iodine organification, as indicated by nega-
tive perchlorate discharge tests.23,24 In pa-
tients with preexisting thyroid abnormalities 
(nodular goiter, “latent” Graves’ disease), the 
24-h thyroidal radioactive iodine uptake 
(RAIU) values are, in type I AIT, inappropri-
ately normal or even increased despite the io-
dine load;25 this phenomenon is rarely ob-
served in iodine sufficient areas, such as 
USA, where RAIU values are almost always 
very low or suppressed, as observed in type II 
AIT (destructive thyroiditis). This suggests 
that in mildly iodine deficient areas, patients 
with preexisting thyroid abnormalities may 
fail to adapt normally to an excessive iodine 
intake, leading to inappropriately normal or 
elevated RAIU values. This subgroup of AIT 
patients usually have normal or slightly ele-
vated serum levels of interleukin-6 (IL-6), a 
good marker of thyroid-destructive proc-
esses,26 implying that in type I AIT patients, 
thyroid-destructive processes play a minor 
pathogenic role. The fact that type I AIT (un-
0
2
4
6
8
10
12
14
16
MONTHS
<5 4-6 7-9 10-12 13-15 19-21 22-24 >25
N
°
 O
F
  
P
A
T
I
E
N
T
S
On Am iodarone 
After W ithdrawal
16-18
56 S. Brogioni et al.  
 
International Journal of Endocrinology and Metabolism  
 
derlying thyroid abnormality, nor-
mal/elevated RAIU values, normal/slightly 
elevated serum IL-6 levels) is indeed related 
to increased iodine-induced thyroid hormone 
synthesis is in keeping with the observation 
that in these cases the observed color flow 
doppler sonography (CFDS) patterns (pattern 
I-III) indicate a hyperfunctioning and hyper-
vascularized thyroid gland, similar to sponta-
neous (amiodarone-unrelated) hyperthyroid-
ism.27 
Type II AIT patients have an apparently 
normal thyroid gland (although in some cases 
there may be a small, tender goiter), no thy-
roid autoimmune phenomena, very 
low/suppressed RAIU values (usually <2-
3%),25 markedly increased serum IL-6 con-
centrations,26 and absence of hypervascular-
ity (CFDS pattern 0).27 These features are 
similar to other thyroidal destructive proc-
esses, such as subacute thyroiditis,28 albeit se-
rum IL-6 determination is not always helpful 
for type II AIT diagnosis.29 Likewise serum 
C-reactive protein (CRP), an acute-phase 
marker, could not correctly differentiate in-
flammatory and noninflammatory thyroid 
disorders; in fact, serum CPR levels did not 
differ significantly in patients with type I and 
type II AIT.30 The destructive nature of type 
II AIT is further supported by the histopa-
thologic examination of the thyroid, which 
demonstrates moderate to severe follicular 
damage and disruption.31 Therefore, thyro-
toxicosis in type II AIT is due to discharge of 
preformed thyroid hormones from damaged 
follicles. In keeping with this concept, the 
thyrotoxic phase is sometimes followed by 
mild hypothyroidism,32 which may be accel-
erated by reexposure of the patient to iodine 
load.33 
The relative prevalence of these two main 
forms of AIT is unknown, but the environ-
mental iodine may be relevant. Indeed, in io-
dine sufficient areas, where the incidence of 
multinodular goiters is very low, virtually 
only destructive-type AIT is observed.34 It 
must underscored that mixed (or undefined) 
forms of AIT may occur probably more fre-
quently than previously recognized; in these 
cases the different pathogenic mechanisms 
and laboratory features of type I and type II 
AIT may coexist, i.e., presence of goiter 
and/or thyroid autoantibodies with markedly 
increased serum IL-6 levels or low/ sup-
pressed RAIU values.25 As indicated by 
many respondents to a questionnaire on AIT 
distributed among members of the European 
Thyroid Association,35 mixed (undefined) 
AIT cases are believed to be relatively fre-
quent and constitute a difficult therapeutic 
problem (see below). 
 
Clinical features 
Clinical picture of AIT may be extremely 
variable. Exacerbation of the underlying car-
diac disorder, particularly the difficulty in 
keeping tachyarrhythmias under proper con-
trol, may be the main clinical feature herald-
ing the development of AIT in a patient un-
der chronic amiodarone treatment.5 Common 
symptoms of thyrotoxicosis may be absent, 
particularly in the elderly; goiter may be pre-
sent or absent, with or without pain in the 
thyroid region; ophthalmopathy is usually ab-
sent, unless AIT develops in a patient with 
previously unrecognized Graves’ disease.5 
Diagnosis of AIT may be a difficult chal-
lenge in patients with severe nonthyroidal ill-
ness, because comorbidity, especially in the 
elderly, may dominate the clinical picture and 
independently cause an increase in serum 
FT4, a decreased/suppressed serum TSH, and 
a reduction in serum total T3 concentration; 
under these circumstances, measurement of 
serum FT3 concentration may, however, be 
useful and decisive in establishing the correct 
diagnosis of thyrotoxicosis.36 Serum thy-
roglobulin concentration is often increased in 
AIT, but this is not a specific and good 
marker of thyroid destruction in goitrous pa-
tients, who often have markedly elevated 
baseline serum thyroglobulin levels.  
 
Management of AIT 
Management of AIT constitutes a major 
challenge and a difficult task (Table 5). Con-
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ventional antithyroid therapy is usually not 
effective in AIT; the high intrathyroidal io-
dine content reduces the efficacy of thiona-
mides,5 while the often low/suppressed RAIU 
values preclude the possibility to treat these 
patients by radioiodine. Identification of the 
two main different subtypes of AIT, which, 
as we mentioned, is not always possible, 
should be pursued to provide a rational basis 
for the choice of the appropriate medical 
treatment and improve the therapeutic out-
come. 
 
Table 5. Management of amiodarone-induced 
thyrotoxicosis 
 Treatment 
Type I AIT Thionamides+Potassium 
Perchlorate 
Thyroidectomy 
Type II AIT Glucocorticoids 
Mixed forms Thionamides+Potassium 
Perchlorate+ 
Glucocorticoids 
 
Treatment of type I AIT 
In type I AIT treatment should be aimed, 
on one hand, at blocking organification of io-
dine, thus inhibiting synthesis of thyroid 
hormones and, on the other, at decreasing 
further entry of iodine into the thyroid, thus 
depleting intrathyroidal iodine stores and 
making thionamide action more effective. 
Thionamides represent a well established 
therapy for spontaneous hyperthyroidism due 
to Graves’ disease, while they should be con-
sidered only a method to control hyperthy-
roidism prior to ablative therapy by either ra-
dioiodine or thyroidectomy for toxic ade-
noma or toxic multinodular goiter.37 In the 
uncomplicated thyrotoxic patient, after the 
first few weeks of therapy with relatively 
high doses of the drug (e.g., 20-30 mg/day 
methimazole), low doses are generally suffi-
cient to maintain euthyroidism.37 In AIT, the 
iodine-repleted thyroid is more resistant to 
thionamides, making necessary the use of 
larger than usual daily doses of methimazole 
(40-60 mg) or propylthiouracil (600-800 
mg).5 Despite the elevated doses of antithy-
roid drugs, patients often remain hyperthy-
roid for several months. This situation is ob-
viously dangerous in view of the underlying 
cardiac conditions, and, in addition, exposes 
the patient to the risk of thionamide-induced 
side effects and complications, which are 
more frequent when high doses of the drug 
are used.38 In a recent survey among mem-
bers of the European Thyroid Association, 
51% of respondents indicated thionamides as 
the first-choice treatment for type I AIT, but 
also suggested in the majority of cases that, 
should the patient still be hyperthyroid after 
few weeks of thionamide administration, po-
tassium perchlorate should be added.35 What 
is the rationale for this association? Potas-
sium perchlorate per se is a weak antithyroid 
drug, but it has important actions that can be 
exploited in AIT. In fact, this drug reduces 
the entry of iodine into the thyroid and ulti-
mately decreases intrathyroidal iodine stores; 
by these means, the efficacy of thionamides 
is improved. Management of AIT by con-
comitant treatment with potassium perchlo-
rate and methimazole was first reported by 
our group in a study of 23 AIT patients who 
were treated with either methimazole (40 mg 
daily) alone, methimazole and potassium 
perchlorate (1 g daily), or were left un-
treated.39 Only the combined treatment con-
trolled thyrotoxicosis in all cases, and re-
stored euthyroidism more rapidly than the 
conventional treatment with methimazole 
alone.39 The major limitation of potassium 
perchlorate is represented by its potential side 
effects, particularly agranulocytosis, aplastic 
anemia, and renal toxicity.38 However, these 
are infrequent if daily doses of the drug do 
not exceed 1 g.40 In any case, it seems pru-
dent to withdraw potassium perchlorate once 
euthyroidism has been restored and, in any 
case, after 5-6 weeks.5 Furthermore, a com-
plete blood count should be made at weekly 
intervals to detect the potential occurrence of 
anemia and/or agranulocytosis. 
The addition of lithium carbonate (900-
1350 mg/day for 4-6 weeks), which decreases 
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thyroid hormone discharge from the gland, to 
propylthiouracil has been reported in a small 
series of AIT patients to shorten substantially 
the time period necessary to achieve euthy-
roidism,41 but these results require confirma-
tion in larger and controlled studies.  
Plasmapheresis can transiently reduce 
plasma amiodarone and DEA concentrations 
and, therefore, produce an improvement of 
clinical status for few days in AIT patients;42 
however, the amount of amiodarone removed 
from the body is quite low (about 1 
mg/plasmapheresis), and this transient im-
provement is often followed by an exacerba-
tion of AIT.43 Accordingly, plasmapheresis 
should be considered a desperate therapeutic 
measure to use when everything else fails. 
Thyroidectomy represents a valid option 
for type I AIT patients resistant to medical 
treatment, although the underlying cardiac 
conditions and the thyrotoxic state may in-
crease the surgical risk or even preclude sur-
gery in some patients.44 Recently we ob-
served that a prompt restoration of euthyroid-
ism before thyroidectomy can be achieved by 
a short course of iopanoic acid.45 A series of 
AIT patients, whose thyrotoxicosis was pre-
viously uncontrolled and inevitably required 
amiodarone as a life-saving drug, were sub-
mitted to safe and uneventful total thyroidec-
tomy: this approach made continuation of 
amiodarone therapy possible.45 In the recent 
survey among members of the European 
Thyroid Association, surgical approach was 
selected by only 1% of respondents as the 
first-line treatment for type I AIT, but this 
proportion increased to 10% when antithy-
roid drugs proved to be ineffective in control-
ling thyrotoxicosis.35 
 
Treatment of type II AIT 
Type II AIT is not a true form of hyperthy-
roidism due to increased thyroid hormone 
synthesis, but rather a destructive thyroiditis 
caused by amiodarone and/or iodine; accord-
ingly, thionamides and potassium perchlorate 
are not effective.5 Conversely, steroids repre-
sent an effective treatment for type II AIT in 
view of their membrane-stabilizing and anti-
inflammatory effects.46 An additional benefi-
cial action of steroids is the inhibition of pe-
ripheral T4 conversion to T3. Almost half of 
respondents to the European Thyroid Asso-
ciation survey indicated steroids as the first-
line treatment for type II AIT.35 Steroids have 
been employed in AIT at different doses (15-
80 mg prednisone or 3-6 mg dexamethasone 
daily) and for different time periods (7-12 
weeks);5 they provided favorable responses, 
either alone or in combination with antithy-
roid drugs, in most studies of patients with 
type II AIT,46,47 whereas in type I AIT, in 
agreement with its pathogenic mechanism, 
this treatment is poorly effective.47 Recur-
rence of thyrotoxicosis is not exceptional fol-
lowing steroid withdrawal:46 this makes rein-
stitution of steroid treatment necessary.  
Oral cholecystographic agents (OCAs) af-
fect peripheral metabolism of the thyroid 
hormones, mainly by inhibiting peripheral 
monodeiodination of T4 to T3,
48 and can be 
used in the treatment of the spontaneous hy-
perthyroidism.49 The use of OCAs was re-
ported in a mixed form of AIT in association 
with thionamides, KCLO4 and glucocorti-
coids, and type II AIT in combination with 
thionamides.50 We recently reported the re-
sults of a randomized, controlled study, in 
which we compared the long-term effects of 
treatment of type II AIT with either steroids 
or iopanoic acid.51 Both treatments were as-
sociated with a rapid decrease in serum FT3 
concentrations, but serum FT4 levels re-
mained markedly elevated for months in pa-
tients receiving iopanoic acid therapy,51 sug-
gesting that iopanoic acid exerts its effects 
almost exclusively on the peripheral T3 gen-
eration from T4 but does not affect the thy-
roidal destructive process as glucocorticoids 
do. Accordingly, steroids must be considered 
the first-choice treatment for type II AIT. 
Iopanoic acid is useful, as in type I AIT, as a 
short-term treatment, in the preparation to 
thyroid surgery.45 
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Mixed (or undefined) forms of AIT 
A major problem physicians face when 
dealing with AIT is its correct classification. 
It seems more evident than in the past, that 
categorization of AIT in type I and type II is 
too schematic. In particular both pathogenic 
mechanisms (true thyroid hormone hyper-
production and destructive phenomena) may 
be concomitantly present in the same AIT pa-
tient. This situation may not be easily detect-
able despite the aid of diagnostic tools 
(ECDS, serum IL-6 measurement, thyroidal 
RAIU determination). This subgroup of AIT 
can be indicated as mixed or, probably better, 
undefined forms. Diagnostic uncertainty was 
underscored by 27% of respondents to the 
European Thyroid Association questionnaire, 
who defined the index case (a typical case of 
type I AIT) as a mixed form.35 These diag-
nostic problems have a relevant impact on the 
therapeutic choice: in fact many thyroidolo-
gists prefer to treat AIT with a combination 
of thionamides (with or without potassium 
perchlorate) and steroids, both in cases of ap-
parently clear-cut type I AIT and, more sur-
prisingly, in patients with evident signs of 
destructive thyroiditis.35 The answer to 
whether this multiple and complex pharma-
cologic approach is justified only in unde-
fined forms of AIT or should be considered 
as the initial treatment in all cases of AIT, 
can only come from large, multicenter, ran-
domized and controlled trials. 
 
Open Questions 
As outlined by the recent survey among 
members of the European Thyroid Associa-
tion,35 there are several areas of uncertainty 
pertaining to AIT. 
Should amiodarone be withdrawn in pa-
tients who develop AIT? This is a major ques-
tion, because amiodarone often represents an 
important (sometimes a life-saving) antiar-
rhythmic drug that cannnot easily be discon-
tinued or replaced. In addition, the long half-
life of amiodarone (and its metabolites) 
causes the persistance of its effects on the 
thyroid gland even long after amiodarone 
discontinuation.9 Remission of thyrotoxicosis 
while amiodarone was continued has been 
reported either spontaneously28 or during an-
tithyroid drug treatment.52,53,54 However, 90% 
of respondents to the European Thyroid As-
sociation questionnaire proposed amiodarone 
withdrawal for the index case (type I AIT) 
and 80% for the case variant (type II AIT).35 
Discontinuation of amiodarone might be as-
sociated with the removal of the “hypothy-
roid-like” effect of the drug on the heart and, 
therefore, an exacerbation of “heart thyro-
toxicosis”. Continuation of amiodarone ther-
apy might be more conceivable in type II 
AIT, which is considered a self-limiting 
process. It is our opinion, in the absence of 
controlled trials, that amiodarone therapy 
should be interrupted, whenever feasible, 
provided that the underlying cardiac situation 
allows this measure. 
How should the thyroid be treated once 
euthyroidism has been restored and amio-
darone has been withdrawn? The answer to 
this question largely depends on whether the 
thyroid gland is abnormal per se and amio-
darone is required to control the underlying 
cardiac abnormalities. Type I AIT occurs in 
an abnormal thyroid gland affected with ei-
ther nodular goiter or Graves’ disease.5 Un-
der these circumstances, in most cases the io-
dine load simply accelerates the natural 
course of the pre existing thyroid disorder. 
Given this premise, we believe that patients 
with type I AIT should be submitted, once 
euthyroidism has been restored and iodine 
contamination removed, to ablative therapy 
by either radioiodine or thyroidectomy. In the 
European Thyroid Association survey35 this 
view was shared only by 34% of respondents, 
whereas 47% indicated that thyroid ablation 
should be carried out only if there is a recur-
rence of thytotoxicosis. In type II AIT the 
thyroid gland is basically normal, and no 
sound information is available on the long-
term natural outcome after this destructive 
process; however, it seems likely that these 
patients remain euthyroid or may become 
hypothyroid either spontaneously or after re-
60 S. Brogioni et al.  
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exposure to iodine (and amiodarone?).55 Ac-
cordingly, we believe that, after recovery 
from type II AIT, ablative therapy should not 
be a target; this view was shared by the ma-
jority of respondents to the European Thyroid 
Association survey.35 
What should be done if amiodarone ther-
apy needs to be reinstituted? While prophy-
lactic radioiodine therapy or thyroidectomy 
was indicated by 65% of respondents to the 
European Thyroid Association questionnaire 
in the index case (type I AIT) and 27% in the 
case variant (type II AIT), follow-up and 
strict monitoring were suggested by 29% in 
the index case and 70% in the case variant.35 
In keeping with previous discussion, it is our 
opinion that thyroid ablation is preferable in 
type I (and undefined forms) AIT, while 
close surveillance may represent the best 
strategy for type II AIT. 
What to do if hypothyroidism occurs after 
reinstitution of amiodarone therapy? As 
mentioned above and recently discussed in a 
Clinical Case Seminar,55 reinstitution of 
amiodarone therapy may be associated with 
the occurrence of hypothyroidism, although 
precise figures on this phenomenon are lack-
ing. Under these circumstances, as also indi-
cated by most European Thyroid Association 
respondents,35 L-T4 replacement should be 
given. Since the hypothyroid phase may be 
transient, a reassessment of the situation few 
months later following L-T4 withdrawal, 
probably represents the best strategy in these 
cases. 
 
Concluding Remarks 
AIT represents a challenging situation, be-
cause of the lower effectiveness of conven-
tional antithyroid treatments and the underly-
ing cardiac abnormalities. A better definition 
of diagnostic criteria and classification is 
warranted, because this may lead to im-
provement of the therapeutic strategy and 
outcome. A strict collaboration between en-
docrinologists and cardiologists is needed for 
a better monitoring of amiodarone-treated pa-
tients and a prompter therapeutic intervention 
once AIT occurs. 
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